David Healy (psychiatrist)

Last updated

David Healy
FRCPsych
David Healy (1997).jpg
Healy in 1997
Born (1954-04-27) 27 April 1954 (age 70)
Raheny, Ireland
Scientific career
Fields Psychiatry
Institutions Bangor University

David Healy FRCPsych , a professor of psychiatry at Bangor University in the United Kingdom, is a psychiatrist, psychopharmacologist, scientist and author. His main areas of research are the contribution of antidepressants to suicide, conflict of interest between pharmaceutical companies and academic medicine, and the history of pharmacology. Healy has written more than 150 peer-reviewed articles, 200 other articles, and 20 books, including The Antidepressant Era, The Creation of Psychopharmacology, The Psychopharmacologists Volumes 1–3, Let Them Eat Prozac and Mania: A Short History of Bipolar Disorder.

Contents

Healy has been involved as an expert witness in homicide and suicide trials involving psychotropic drugs, and has brought concerns about some medications to the attention of drug regulators. He has also said that pharmaceutical companies sell drugs by marketing diseases and co-opting academic opinion-leaders. In his 2012 book Pharmageddon he argues that pharmaceutical companies have dominated healthcare in America, often with life-threatening results for patients. Healy is a founder and chief executive officer of Data Based Medicine Limited, which aims to make medicines safer through "online direct patient reporting of drug effects".

Career

David Healy originally trained in Dublin, Ireland, and at Cambridge University. He is a former Secretary of the British Association for Psychopharmacology. He is currently a professor of psychiatry at Bangor University in the United Kingdom, a psychiatrist, psychopharmacologist, scientist, and author. His main areas of research are the development and history of psychopharmacology, and the impact of psychotropic drugs on our culture. Healy has written more than 150 peer-reviewed articles, 200 other articles, and 20 books, including The Antidepressant Era and The Creation of Psychopharmacology from Harvard University Press, The Psychopharmacologists Volumes 1–3 and Let Them Eat Prozac from New York University Press, and Mania: A Short History of Bipolar Disorder from Johns Hopkins University Press. [1]

Healy has been involved as a legal expert witness in homicide and suicide trials involving psychotropic drugs, and has brought concerns about some drugs to the attention of American and British regulators. He has alleged that pharmaceutical companies sell drugs by marketing diseases and co-opting academic opinion-leaders, sometimes ghostwriting their articles. His most recent book, Pharmageddon, claims that pharmaceutical companies have dominated healthcare in America, often with life-threatening results for patients. In 2000 a lucrative job at Toronto's Centre for Addiction and Mental Health was withdrawn under unclear circumstances. Healy and his supporters have claimed that this withdrawal was due to Healy giving a speech and publishing a paper claiming that the SSRI antidepressant fluoxetine increases the risk that patients will commit suicide. Lilly was a major contributor to the Centre at the time. [2] A settlement was reached, in which Healy received a visiting professor appointment, and a joint statement was released stating "Although Dr Healy believes that his clinical appointment was rescinded because of his November 2000 speech at the CAMH [Centre for Addiction and Mental Health], Dr Healy accepts assurances that pharmaceutical companies played no role in either CAMH's decision to rescind his clinical appointment or the University of Toronto's decision to rescind his academic appointment." [3]

Healy directs an Electroconvulsive Therapy (ECT) clinic in Wales. He strongly defends the procedure as having an immediate visible effect in severely depressed patients for whom no other options have worked, particularly geriatric patients. He has co-written a history of ECT along with Edward Shorter and cites Max Fink as a source. [4] [5] Healy has clarified which chapters he wrote and that he was not personally financially supported by Fink's Scion Foundation. [6] Another reforming psychiatrist, Peter Breggin, has strongly criticised Healy for this aspect of his work on the grounds of ethics and the longer-term data. [7] Healy has even speculated that Insulin coma therapy may have 'worked' in the sense of generating enthusiasm in staff and in an unclear way to challenge anxiety or 'psychosis', despite a lack of, or contrary, evidence from the time. [8] He has also been criticized for portraying psychiatrists as greedy and duped. [9]

Healy is a founder and chief executive officer of Data Based Medicine Limited, which operates through its website RxISK.org, which aims to make medicines safer through "online direct patient reporting of drug effects". Healy sits on the Honorary International Editorial Advisory Board of the Mens Sana Monographs. [10]

In 2020 Healy's book The Decapitation of Healthcare - A Short History of the Rise and Fall of Healthcare was published by Samizdat Health Writers' Co-operative, the first of a series.[ citation needed ]Ref Rxisk blog and David Healy Blog Feb 2020

Research interests

SSRI antidepressants and suicide

In an international review article, Healy (and Aldred) say that the idea that antidepressants might contribute to suicide in depressed patients was first raised in 1958. For 30 years antidepressants were primarily used in severely depressed and often hospitalised patients. The issue of suicidality on selective serotonin reuptake inhibitors (SSRIs) became one of public concern with reports in 1990 that Prozac could lead to suicidality in patients. [11] Fourteen years later, warning labels were put on antidepressants suggesting particular difficulties "during the early phase of treatment, during treatment discontinuation, and when the dose of treatment is being changed, and that treatment related risks may be present in patients being treated for syndromes other than depression, such as anxiety or smoking cessation". [11]

Healy has written many papers and presented many lectures on his view that all SSRI antidepressants – Prozac, Paxil and Zoloft – should show warning labels, as they could "trigger suicidal and violent behavior in some patients". [12]

Conflict of interest

Healy says that the pharmaceutical industry has a pervasive influence on academic medicine. Most of the authors published in the Journal of the American Medical Association have received research funding from, or acted as a consultant for, a drug company. [13] Major journals have expressed concern at the ghostwriting of and conflicting interests surrounding pharmacotherapeutic studies, especially in psychiatry. [13]

Medical ghostwriting occurs when anonymous scribes with scientific backgrounds are paid to produce reports for publication as if written by better-known experts. Healy estimates that 50 per cent of literature on drugs is ghostwritten/abnormally written. [14] This is an estimate by Healy offered under questioning before the UK House of Commons Health Select Committee investigation. [15] It is based on extrapolation of a 57% figure from a published paper by Healy and Cattell reliant on hard evidence on a set of papers on Zoloft which came to light due to legal discovery, to the wider field of drug studies in top quality journals. [15] [16] [15] In his thesis, Healy states that ghostwriters write on research given to them by drug companies, which want both positive results and positive research; therefore ghostwriting is biased from the beginning.

Healy allegedly encountered ghost writing involving Wyeth's SNRI Effexor. Healy attended a meeting promoting Effexor, and was offered for his approval a draft article that had been written for him. He left it intact, but made two additions. One contradicted Wyeth's claim that Effexor got patients fully well compared to patients on other SSRIs and another stated that SSRIs could make some individuals suicidal. The article had already been submitted to the Journal of Psychiatry and Neuroscience before Healy saw it again; both of his additions had been removed. In response Healy removed his name from the article. [17]

In the preface of his book Let them Eat Prozac Healy describes the need for a "new contract between society and the pharmaceutical industry – a contract that will require access to the raw data". Healy suggests a new division that can manage the hazards that only becomes visible after products are launched. This new division would be separate from the regulatory bodies and pharmaceutical companies. In "Interface between authorship, industry and science in the domain of therapeutics" [18] a paper of 2003 for The British Journal of Psychiatry, David Healy notes that

"The literature profiles and citation rates of industry-linked and non-industry-linked articles differ. The emerging style of authorship in industry-linked articles can deliver good-quality articles, but it raises concerns for the scientific base of therapeutics … If ghostwriting is an inevitable feature of modern scientific writing, the potential availability of the raw data would do more to ensure a correspondence between those data and a published end result than could be achieved by any other mechanism". [18]

History of pharmacology

In his book 2012 Pharmageddon, Healy discusses the well-publicised birth defects crisis caused by thalidomide, a drug initially marketed as a sleeping pill. The 1962 disaster involved more than 10,000 children in 46 countries being born limbless and disabled. The United States Congress wanted to prevent a recurrence of such a tragedy, and sought to limit the marketing excesses of the pharmaceutical industry. So new drug development was rewarded with product rather than process patents, and new drugs were made available only through prescription. Also, new medications had to prove they worked through controlled trials before they reached the market. On the 50th anniversary of the 1962 FDA bill enacted by Congress, Pharmageddon argues that these arrangements have not been successful and have actually led to an escalating number of drug induced deaths and injuries. [19] In the same book ("Pharmageddon" page 155), Healy states that in the United States, the country that makes the greatest use of the latest pharmaceuticals, life expectancy has been falling progressively further behind other developed countries since the mid-1970s.

Bibliography

Books

Selected articles

SSRI Antidepressants and suicide

Conflict of interest

History of pharmacology

Medication-induced sexual dysfunction

See also

Related Research Articles

<span class="mw-page-title-main">Antidepressant</span> Class of medication used to treat depression and other conditions

Antidepressants are a class of medications used to treat major depressive disorder, anxiety disorders, chronic pain, and addiction.

<span class="mw-page-title-main">Major depressive disorder</span> Mood disorder

Major depressive disorder (MDD), also known as clinical depression, is a mental disorder characterized by at least two weeks of pervasive low mood, low self-esteem, and loss of interest or pleasure in normally enjoyable activities. Introduced by a group of US clinicians in the mid-1970s, the term was adopted by the American Psychiatric Association for this symptom cluster under mood disorders in the 1980 version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III), and has become widely used since. The disorder causes the second-most years lived with disability, after lower back pain.

<span class="mw-page-title-main">Tricyclic antidepressant</span> Class of medications

Tricyclic antidepressants (TCAs) are a class of medications that are used primarily as antidepressants. TCAs were discovered in the early 1950s and were marketed later in the decade. They are named after their chemical structure, which contains three rings of atoms. Tetracyclic antidepressants (TeCAs), which contain four rings of atoms, are a closely related group of antidepressant compounds.

A psychiatric or psychotropic medication is a psychoactive drug taken to exert an effect on the chemical makeup of the brain and nervous system. Thus, these medications are used to treat mental illnesses. These medications are typically made of synthetic chemical compounds and are usually prescribed in psychiatric settings, potentially involuntarily during commitment. Since the mid-20th century, such medications have been leading treatments for a broad range of mental disorders and have decreased the need for long-term hospitalization, thereby lowering the cost of mental health care. The recidivism or rehospitalization of the mentally ill is at a high rate in many countries, and the reasons for the relapses are under research.

<span class="mw-page-title-main">Paroxetine</span> SSRI antidepressant medication

Paroxetine, sold under the brand name Paxil among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, social anxiety disorder, post-traumatic stress disorder, generalized anxiety disorder, and premenstrual dysphoric disorder. It has also been used in the treatment of premature ejaculation and hot flashes due to menopause. It is taken orally.

<span class="mw-page-title-main">Sertraline</span> Antidepressant (SSRI class) medication

Sertraline, sold under the brand name Zoloft among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. The effectiveness of sertraline for depression is similar to that of other antidepressants such as Fluoxetine or Paroxetine. Sertraline is better tolerated than the older tricyclic antidepressants. Sertraline is effective for panic disorder, social anxiety disorder, generalized anxiety disorder, and obsessive–compulsive disorder (OCD). Although approved for post-traumatic stress disorder (PTSD), findings have shown sertraline leads to only modest improvements in symptoms. Sertraline also alleviates the symptoms of premenstrual dysphoric disorder and can be used in sub-therapeutic doses or intermittently for its treatment.

<span class="mw-page-title-main">Citalopram</span> SSRI antidepressant

Citalopram, sold under the brand name Celexa among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used to treat major depressive disorder, obsessive compulsive disorder, panic disorder, and social phobia. The antidepressant effects may take one to four weeks to occur. It is typically taken orally. In some European countries, it is sometimes given intravenously to initiate treatment, before switching to the oral route of administration for continuation of treatment. It has also been used intravenously in other parts of the world in some other circumstances.

<span class="mw-page-title-main">Akathisia</span> Movement disorder involving a feeling of inner restlessness

Akathisia is a movement disorder characterized by a subjective feeling of inner restlessness accompanied by mental distress and/or an inability to sit still. Usually, the legs are most prominently affected. Those affected may fidget, rock back and forth, or pace, while some may just have an uneasy feeling in their body. The most severe cases may result in poor adherence to medications, exacerbation of psychiatric symptoms, and, because of this, aggression, violence, and/or suicidal thoughts. Akathisia is also associated with threatening behaviour and physical aggression in mentally disordered patients. However, the attempts to find potential links between akathisia and emerging suicidal or homicidal behaviour were not systematic and were mostly based on a limited number of case reports and small case series. Apart from these few low-quality studies, there is another more recent and better quality study that concludes akathisia cannot be reliably linked to the presence of suicidal behaviour in patients treated with antipsychotic medication.

<span class="mw-page-title-main">Venlafaxine</span> Antidepressant medication

Venlafaxine, sold under the brand name Effexor among others, is an antidepressant medication of the serotonin–norepinephrine reuptake inhibitor (SNRI) class. It is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. Studies have shown that venlafaxine improves post-traumatic stress disorder (PTSD). It may also be used for chronic neuropathic pain. It is taken orally. It is also available as the salt venlafaxine besylate in an extended-release formulation.

<span class="mw-page-title-main">Serotonin–norepinephrine reuptake inhibitor</span> Class of antidepressant medication

Serotonin–norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressant medications used to treat major depressive disorder (MDD), anxiety disorders, social phobia, chronic neuropathic pain, fibromyalgia syndrome (FMS), and menopausal symptoms. Off-label uses include treatments for attention-deficit hyperactivity disorder (ADHD), and obsessive–compulsive disorder (OCD). SNRIs are monoamine reuptake inhibitors; specifically, they inhibit the reuptake of serotonin and norepinephrine. These neurotransmitters are thought to play an important role in mood regulation. SNRIs can be contrasted with the selective serotonin reuptake inhibitors (SSRIs) and norepinephrine reuptake inhibitors (NRIs), which act upon single neurotransmitters.

<span class="mw-page-title-main">Clomipramine</span> Antidepressant

Clomipramine, sold under the brand name Anafranil among others, is a tricyclic antidepressant (TCA). It is used in the treatment of various conditions, most notably obsessive–compulsive disorder but also many other disorders, including hyperacusis, panic disorder, major depressive disorder, trichotillomania, body dysmorphic disorder and chronic pain. It has also been notably used to treat premature ejaculation and the cataplexy associated with narcolepsy.

Antidepressant discontinuation syndrome, also called antidepressant withdrawal syndrome, is a condition that can occur following the interruption, reduction, or discontinuation of antidepressant medication following its continuous use of at least a month. The symptoms may include flu-like symptoms, trouble sleeping, nausea, poor balance, sensory changes, akathisia, intrusive thoughts, depersonalization and derealization, mania, anxiety, and depression. The problem usually begins within three days and may last for several weeks or months. Psychosis may rarely occur.

<span class="mw-page-title-main">Agomelatine</span> Atypical antidepressant classified primarily as a melatonin receptor agonist

Agomelatine, sold under the brand names Valdoxan and Thymanax, among others, is an atypical antidepressant most commonly used to treat major depressive disorder and generalized anxiety disorder. One review found that it is as effective as other antidepressants with similar discontinuation rates overall but fewer discontinuations due to side effects. Another review also found it was similarly effective to many other antidepressants.

<span class="mw-page-title-main">Fluoxetine</span> SSRI antidepressant

Fluoxetine, sold under the brand name Prozac, among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used for the treatment of major depressive disorder, obsessive–compulsive disorder (OCD), anxiety, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It is also approved for treatment of major depressive disorder in adolescents and children 8 years of age and over. It has also been used to treat premature ejaculation. Fluoxetine is taken by mouth.

<span class="mw-page-title-main">Indalpine</span> Discontinued SSRI antidepressant drug

Indalpine, sold under the brand name Upstène, is a selective serotonin reuptake inhibitor (SSRI) that was briefly marketed as an antidepressant for treatment of depression. It was marketed in France and a few other European countries.

Challenge–dechallenge–rechallenge (CDR) is a medical testing protocol in which a medicine or drug is administered, withdrawn, then re-administered, while being monitored for adverse effects at each stage. The protocol is used when statistical testing is inappropriate due to an idiosyncratic reaction by a specific individual, or a lack of sufficient test subjects and unit of analysis is the individual. During the dechallenge (withdrawal) phase, the medication is allowed to wash out of the system in order to determine what effect the medication is having on an individual.

<span class="mw-page-title-main">Selective serotonin reuptake inhibitor</span> Class of antidepressant medication

Selective serotonin reuptake inhibitors (SSRIs) are a class of drugs that are typically used as antidepressants in the treatment of major depressive disorder, anxiety disorders, and other psychological conditions.

The relationship between antidepressant use and suicide risk is a subject of medical research and has faced varying levels of debate. This problem was thought to be serious enough to warrant intervention by the U.S. Food and Drug Administration to label greater likelihood of suicide as a risk of using antidepressants. Some studies have shown that the use of certain antidepressants correlate with an increased risk of suicide in some patients relative to other antidepressants. However, these conclusions have faced considerable scrutiny and disagreement: A multinational European study indicated that antidepressants decrease risk of suicide at the population level, and other reviews of antidepressant use claim that there is not enough data to indicate antidepressant use increases risk of suicide.

<span class="mw-page-title-main">Study 329</span> Scientific article

Study 329 was a clinical trial which was conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating 12- to 18-year-olds diagnosed with major depressive disorder. Led by Martin Keller, then professor of psychiatry at Brown University, and funded by the British pharmaceutical company SmithKline Beecham—known since 2000 as GlaxoSmithKline (GSK)—the study compared paroxetine with imipramine, a tricyclic antidepressant, and placebo. SmithKline Beecham had released paroxetine in 1991, marketing it as Paxil in North America and Seroxat in the UK. The drug attracted sales of $11.7 billion in the United States alone from 1997 to 2006, including $2.12 billion in 2002, the year before it lost its patent.

<span class="mw-page-title-main">David Taylor (professor)</span>

David Taylor FFRPS FRPharmS is a British professor. He is the head of the Pharmaceutical Sciences Clinical Academic Group within King's Health Partners. Taylor has been lead author and editor of the Maudsley Prescribing Guidelines in Psychiatry since 1994. In 2014, Taylor was named as one of the top 100 clinical leaders in the UK National Health Service.

References

  1. ↑ "Dr David Healy Bio". Archived from the original on 12 May 2015. Retrieved 13 August 2013.
  2. ↑ Sept 24th 2001 Press Conference Transcript
  3. ↑ Spurgeon D (2002). "Psychiatrist settles dispute with Toronto University". BMJ. 324 (7347): 1177. doi:10.1136/bmj.324.7347.1177/a. PMC   1174757 .
  4. ↑ Max Fink, M. D. (12 August 2010). "The Perplexing History of ECT in Three Books | Psychiatric Times". Psychiatric Times. Psychiatric Times Vol 27 No 10. 27 (10). Archived from the original on 12 September 2017. Retrieved 12 September 2017.
  5. ↑ Rifkin, Arthur (10 January 2008). "Book Review". New England Journal of Medicine. 358 (2): 205–206. doi:10.1056/NEJMbkrev59202. ISSN   0028-4793.
  6. ↑ "'Let them Eat Prozac' Website - Academic Stalking - Shock Therapy Controversy". www.healyprozac.com. Retrieved 12 September 2017.
  7. ↑ Breggin, Dr Peter (16 February 2012). "The Stealth ECT Psychiatrist in Psychiatric Reform". HuffPost. Retrieved 12 September 2017.
  8. ↑ Kragh, Jesper Vaczy (July 2010). "Shock Therapy in Danish Psychiatry". Medical History. 54 (3): 341–364. doi:10.1017/s0025727300004646. ISSN   0025-7273. PMC   2889500 . PMID   20592884.
  9. ↑ Langford AE (25 April 2015). "Healy does a disservice to psychiatrists". The BMJ . 350: h2508. doi:10.1136/bmj.h2508. PMID   25975809. S2CID   42062976.
  10. ↑ Hon Int Ed Adv Board of the Mens Sana Monographs
  11. 1 2 Healy D, Aldred G (2005). "Antidepressant drug use and the risk of suicide" (PDF). International Review of Psychiatry. 17 (3): 163–172. doi:10.1080/09540260500071624. PMID   16194787. S2CID   6599566. Archived from the original (PDF) on 21 October 2013.
  12. ↑ David Healy's Website
  13. 1 2 Healy D, Thase M (2003). "Is academic psychiatry for sale?" (PDF). British Journal of Psychiatry. 182 (5): 1–3. doi: 10.1192/bjp.maydeb . PMID   12724241.
  14. ↑ Barnett, Antony (7 December 2003). "Revealed: how drug firms 'hoodwink' medical journals". The Observer. Retrieved 11 April 2017.
  15. 1 2 3 Stretton S (2014). "Systematic review on the primary and secondary reporting of the prevalence of ghostwriting in the medical literature". BMJ Open. 4 (7): e004777. doi:10.1136/bmjopen-2013-004777. PMC   4120312 . PMID   25023129.
  16. ↑ Healy, D; Cattell, D (2003). "Interface between authorship, industry and science in the domain of therapeutics". The British Journal of Psychiatry. 183: 22–7. doi: 10.1192/bjp.183.1.22 . PMID   12835239.
  17. ↑ Boseley, Sarah (7 February 2002). "It said the drug was the best thing since sliced bread. I don't think it is". The Guardian. Retrieved 11 April 2017.
  18. 1 2 Healy, David; Cattell, Dinah (2003). "Interface between authorship, industry and science in the domain of therapeutics". British Journal of Psychiatry. 183: 22–27. doi: 10.1192/bjp.183.1.22 . S2CID   8727777.
  19. ↑ Pharmageddon
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.